SCHEMBL2155377

SCHEMBL2155377

CCCCCC#CC(CS(=O)(=O)N1CCN(c2ccc(OC)c(OC)c2)CC1)ONC=O

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
PKM P14618 1/20 0.37
DPP4 P27487 2/20 0.35
MAPT P10636 1/20 0.34
THRB P10828 2/20 0.34
CYP3A4 P08684 1/20 0.33
MMP13 P45452 1/20 0.33
MMP14 P50281 1/20 0.33
CTSB P07858 1/20 0.33
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33
MAPK1 P28482 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
HTT P42858 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KDM4E B2RXH2 1/20 0.32
SUV39H2 Q9H5I1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2155666 0.86 KDM4E (0.39) LMNAMAPTCYP3A4MMP13MMP14
SCHEMBL2154992 0.85 LMNA (0.41) LMNAMAPTMEN1KMT2A
SCHEMBL2154936 0.85 MAPT (0.33) PKMMAPTCYP3A4MMP13MMP14
SCHEMBL16493584 0.85 PKM (0.41) LMNAPKMDPP4MAPTTHRB
SCHEMBL16493585 0.85 LMNA (0.41) LMNAPKMDPP4MAPTTHRB
SCHEMBL2156070 0.84 POLB (0.40) LMNAMAPTCYP3A4MMP13MMP14
SCHEMBL2156509 0.83 LMNA (0.41) LMNAPKMDPP4THRBCTSB
SCHEMBL2156329 0.83 MMP13 (0.48) LMNAMAPTCYP3A4MMP13MMP14
SCHEMBL2155381 0.82 MMP13 (0.44) LMNAPKMDPP4THRBCYP3A4
SCHEMBL2155252 0.81 POLB (0.38) LMNAMAPTCYP3A4MMP13MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973039-B2 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors MERCK SERONO SA (CH) 2011-07-05 US claimed
EP-1828160-B1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS MERCK SERONO SA (CH) 2011-12-14 EP disclosed
US-7973039-B2 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors MERCK SERONO SA (CH) 2011-07-05 US disclosed
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof MERCK SERONO SA (CH) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof GLS2, SRM, GLS LMNA 3423/4885PKM 1039/4885DPP4 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.